Assessing Bone Formation and Resorption Balance Using Reference Turnover Markers
Overview
This study developed a bone balance index (BBI) combining serum CTX and PINP markers to estimate net bone formation relative to resorption in women transitioning through menopause. More negative BBI values predicted faster bone mineral density (BMD) loss at the lumbar spine and femoral neck, outperforming individual markers alone.
Background
Bone turnover markers (BTMs) reflect osteoclast and osteoblast activity but individually cannot indicate net bone gain or loss due to coupled resorption and formation processes. Combining resorption and formation markers into a composite index may better estimate bone balance and predict changes in bone mineral density. The Study of Women's Health Across the Nation (SWAN) cohort provides longitudinal data to validate such an index during the menopause transition, a period of accelerated bone loss.
Data Highlights
Marker
Association with Annual BMD Decline (%)
Site
P-value
BBI (per SD decrement)
0.26
Lumbar Spine
<.0001
BBI (per SD decrement)
0.42
Femoral Neck
<.0001
CTX (per SD increment, log2)
0.37
Lumbar Spine
<.0001
CTX (per SD increment, log2)
0.47
Femoral Neck
<.0001
PINP (per SD increment, log2)
0.22
Lumbar Spine
<.0001
PINP (per SD increment, log2)
0.19
Femoral Neck
0.01
Key Findings
The bone balance index (BBI), combining CTX and PINP, estimates net bone formation relative to resorption; more negative BBI values indicate less favorable bone balance.
Each standard deviation decrease in BBI was associated with a 0.26% greater annual decline in lumbar spine BMD and 0.42% greater decline in femoral neck BMD (P < .0001).
Higher individual levels of CTX or PINP were independently associated with faster BMD loss, reflecting increased overall bone turnover.
CTX showed a stronger association with BMD decline than PINP, consistent with its greater sensitivity and lower variability.
The BBI provides a more direct estimate of bone balance compared to individual BTMs, potentially improving prediction of bone loss during menopause transition.
Clinical Implications
The BBI may serve as a useful biomarker to identify women at higher risk of accelerated bone loss during menopause by integrating bone resorption and formation markers. Monitoring BBI alongside individual BTMs could enhance clinical assessment of bone health and guide timely interventions to prevent osteoporosis. Using recommended serum markers CTX and PINP improves measurement reliability for longitudinal bone turnover evaluation.
Conclusion
Combining serum CTX and PINP into a bone balance index offers a novel approach to estimate net bone remodeling balance and predict bone mineral density loss during menopause. This integrated marker may improve clinical and research assessments of bone health beyond individual turnover markers alone.
References
Study of Women's Health Across the Nation (SWAN) -- Bone Turnover Markers and Menopause Transition
International Osteoporosis Foundation and IFCC -- Recommendations on Bone Turnover Markers
In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.